R&D Systems™ Recombinant Human IFN-alpha-2B Protein

Description

Recombinant Protein

Measured in anti-viral assays using HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. Meager, A. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 129. The ED50 fot this effect is 3.00-60.0 pg/mL.

Specifications

• Accession Number: NP_000596.2
• For Use With (Application): Bioactivity
• Formulation: Lyophilized from a 0.2 μm filtered solution in PBS.
• Gene ID (Entrez): 3440
• Molecular Weight (g/mol): M.W.-observed: 18-22 kDa, under reducing conditions., M.W.-theroretical: 19 kDa
• Quantity: 10 μg
• Source: Human embryonic kidney cell, HEK293-derived human IFN-alpha protein Cys24-Glu188
• Storage Requirements: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20°C to -70°C as supplied. 1 month, 2°C to 8°C under sterile conditions after reconstitution. 3 months, -20°C to -70°C under sterile conditions after reconstitution.
• Endotoxin Concentration: <0.10 EU / 1 μg of the protein by the LAL method.
• Gene Alias: IFNA, IFNA2, IFNA2b, IFNalpha, IFN-alphaA, INFA2, interferon alpha 2, LeIF D
• Conjugate: Unconjugated
• Reconstitution: Reconstitute at 100 μg/mL in PBS.
• Purity or Quality Grade: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie™ Blue Staining.
• Protein: IFN-alpha